Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Medtronic Talent Stent-Graft-System · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Anti-hypertensive medical treatment |
| Name | Type | Description |
|---|---|---|
| Medtronic Talent Stent-Graft-System | DEVICE | - |
Inclusion Criteria: * No contraindication for an anesthetic procedure with intubation * Type B aortic dissection that occurred 2-52 weeks before randomization * Diameter of the targeted aortic segment ≤6 cm * Aortic kinking \<75° * The subject or legal guardian understands the nature of the study a...
The Medtronic Talent Stent-Graft-System is used for aortic diseases, specifically in the treatment of patients with type B aortic dissection. It is an investigational device being studied in a Phase 3 clinical trial to evaluate its safety and effectiveness in this patient population.
The Medtronic Talent Stent-Graft-System is developed by Rhythm Pharmaceuticals, Inc. (ticker: RYTM). The company is conducting clinical research on this device for the treatment of aortic diseases.
The Medtronic Talent Stent-Graft-System is in Phase 3 clinical development. It is an investigational device and has not been approved by regulatory authorities. One Phase 3 trial has been completed to evaluate its use in patients with type B aortic dissection.
The Medtronic Talent Stent-Graft-System was studied in the INSTEAD Trial (NCT00525356), a Phase 3, active-controlled, randomized study. The trial enrolled 136 patients with aortic diseases in the Netherlands and has been completed.
The Medtronic Talent Stent-Graft-System is the device evaluated in the INSTEAD Trial (NCT00525356), which stands for INvestigation of STEnt Grafts in Patients With Type B Aortic Dissection. The trial compared the stent-graft system against an active control in 136 patients.